Difference between steroid and prp injection in plantar facitis

Reading File

Finding Sources

Searching PubMed

"plantar fasciitis" AND platelet-rich plasma AND corticosteroid

Searching the Web

PRP vs corticosteroid injection plantar fasciitis comparison efficacy

Reading File

Steroid vs PRP Injection for Plantar Fasciitis

Both are used for chronic plantar fasciitis that hasn't responded to conservative measures (stretching, orthotics, NSAIDs, night splints), but they work differently and have different risk/benefit timelines.

1. Mechanism

Corticosteroid injection: An anti-inflammatory that suppresses local inflammation and pain signaling. It does not address the underlying tissue degeneration seen in chronic plantar fasciitis (which is more degenerative/fasciosis than purely inflammatory).
PRP (platelet-rich plasma): Autologous blood product concentrated with platelets and growth factors, injected to stimulate the natural healing/regenerative response of the fascia rather than just suppressing symptoms.

2. Speed of relief

Steroid: Faster onset - patients often notice pain relief within days.
PRP: Delayed onset - improvement typically builds over several weeks, with best results often seen months later.

3. Durability of relief

Steroid: Relief tends to be short-lived. A Cochrane review found steroid injections produced significant improvement at 1 month but not at 3 or 6 months compared with control - Roberts and Hedges' Clinical Procedures in Emergency Medicine.
PRP: Comparative studies show that although steroid gives faster relief, PRP provides greater and longer-lasting pain relief, with improvement persisting out to 2 years in some series - Campbell's Operative Orthopaedics, 15th Ed.
Multiple RCTs/meta-analyses (e.g., a 2020 systematic review of 653 patients) found PRP produced significantly lower pain scores than steroid at 6 months, 1 year, and 1.5 years follow-up, with better functional (foot/ankle) outcomes at mid-term.

4. Safety/risk profile

Steroid: Carries a real risk of plantar fascia rupture, along with fat pad atrophy and local tissue weakening, especially with repeated injections - Rheumatology, 2-Volume Set. This is the main reason many clinicians limit steroid injections to one, or avoid repeat dosing.
PRP: Being autologous, it avoids allergic/foreign-body reaction risk, and does not carry the fascia-rupture or fat-pad-atrophy risk associated with steroids. Downsides are cost, need for blood draw/processing, and less standardization of preparation protocols across studies.

5. Cost and practicality

Corticosteroid injection is cheaper, quicker to prepare, and technically simpler to perform - some reviews note there is no strong evidence that PRP (or botulinum toxin) outperforms corticosteroid injection enough to justify the added cost and complexity for every patient, though newer meta-analyses increasingly favor PRP for longer-term outcomes.

Bottom line

	Corticosteroid	PRP
Onset	Fast (days)	Slow (weeks)
Duration of benefit	Short (weeks to ~1 month)	Long (months to years)
Mechanism	Anti-inflammatory	Regenerative
Key risk	Fascia rupture, fat pad atrophy	Minimal (autologous), higher cost
Cost/convenience	Low cost, simple	Higher cost, more involved prep

In practice, many clinicians use steroid for a quick "rescue" of severe acute pain but favor PRP when the goal is longer-term resolution of chronic, recalcitrant plantar fasciitis, given emerging evidence of more durable improvement without the rupture risk.

Recent evidence check: A 2025 systematic review/meta-analysis (Zuo et al., PMID 39778212) and a 2023 meta-analysis on corticosteroid injections (Seth et al., PMID 36774828) both broadly support the pattern above - PRP shows superior mid- to long-term pain/function outcomes, while corticosteroid gives quicker but less durable relief. These don't contradict the textbook guidance, but confirm PRP's advantage is more consistently supported in recent literature than older textbooks suggested.

Write aa short note on bmp

BMP can refer to a couple of different things in medicine - let me confirm which one you mean.

Asking for Preferences

Steroid vs PRP Injection for Plantar Fasciitis

Both are used for chronic plantar fasciitis that hasn't responded to conservative measures (stretching, orthotics, NSAIDs, night splints), but they work differently and have different risk/benefit timelines.

1. Mechanism

Corticosteroid injection: An anti-inflammatory that suppresses local inflammation and pain signaling. It does not address the underlying tissue degeneration seen in chronic plantar fasciitis (which is more degenerative/fasciosis than purely inflammatory).
PRP (platelet-rich plasma): Autologous blood product concentrated with platelets and growth factors, injected to stimulate the natural healing/regenerative response of the fascia rather than just suppressing symptoms.

2. Speed of relief

Steroid: Faster onset - patients often notice pain relief within days.
PRP: Delayed onset - improvement typically builds over several weeks, with best results often seen months later.

3. Durability of relief

Steroid: Relief tends to be short-lived. A Cochrane review found steroid injections produced significant improvement at 1 month but not at 3 or 6 months compared with control - Roberts and Hedges' Clinical Procedures in Emergency Medicine.
PRP: Comparative studies show that although steroid gives faster relief, PRP provides greater and longer-lasting pain relief, with improvement persisting out to 2 years in some series - Campbell's Operative Orthopaedics, 15th Ed.
Multiple RCTs/meta-analyses (e.g., a 2020 systematic review of 653 patients) found PRP produced significantly lower pain scores than steroid at 6 months, 1 year, and 1.5 years follow-up, with better functional (foot/ankle) outcomes at mid-term.

4. Safety/risk profile

Steroid: Carries a real risk of plantar fascia rupture, along with fat pad atrophy and local tissue weakening, especially with repeated injections - Rheumatology, 2-Volume Set. This is the main reason many clinicians limit steroid injections to one, or avoid repeat dosing.
PRP: Being autologous, it avoids allergic/foreign-body reaction risk, and does not carry the fascia-rupture or fat-pad-atrophy risk associated with steroids. Downsides are cost, need for blood draw/processing, and less standardization of preparation protocols across studies.

5. Cost and practicality

Corticosteroid injection is cheaper, quicker to prepare, and technically simpler to perform - some reviews note there is no strong evidence that PRP (or botulinum toxin) outperforms corticosteroid injection enough to justify the added cost and complexity for every patient, though newer meta-analyses increasingly favor PRP for longer-term outcomes.

Bottom line

	Corticosteroid	PRP
Onset	Fast (days)	Slow (weeks)
Duration of benefit	Short (weeks to ~1 month)	Long (months to years)
Mechanism	Anti-inflammatory	Regenerative
Key risk	Fascia rupture, fat pad atrophy	Minimal (autologous), higher cost
Cost/convenience	Low cost, simple	Higher cost, more involved prep

In practice, many clinicians use steroid for a quick "rescue" of severe acute pain but favor PRP when the goal is longer-term resolution of chronic, recalcitrant plantar fasciitis, given emerging evidence of more durable improvement without the rupture risk.

Recent evidence check: A 2025 systematic review/meta-analysis (Zuo et al., PMID 39778212) and a 2023 meta-analysis on corticosteroid injections (Seth et al., PMID 36774828) both broadly support the pattern above - PRP shows superior mid- to long-term pain/function outcomes, while corticosteroid gives quicker but less durable relief. These don't contradict the textbook guidance, but confirm PRP's advantage is more consistently supported in recent literature than older textbooks suggested.BMP can refer to a couple of different things in medicine - let me confirm which one you mean.

Asking for Preferences

Steroid vs PRP Injection for Plantar Fasciitis

Both are used for chronic plantar fasciitis that hasn't responded to conservative measures (stretching, orthotics, NSAIDs, night splints), but they work differently and have different risk/benefit timelines.

1. Mechanism

Corticosteroid injection: An anti-inflammatory that suppresses local inflammation and pain signaling. It does not address the underlying tissue degeneration seen in chronic plantar fasciitis (which is more degenerative/fasciosis than purely inflammatory).
PRP (platelet-rich plasma): Autologous blood product concentrated with platelets and growth factors, injected to stimulate the natural healing/regenerative response of the fascia rather than just suppressing symptoms.

2. Speed of relief

Steroid: Faster onset - patients often notice pain relief within days.
PRP: Delayed onset - improvement typically builds over several weeks, with best results often seen months later.

3. Durability of relief

Steroid: Relief tends to be short-lived. A Cochrane review found steroid injections produced significant improvement at 1 month but not at 3 or 6 months compared with control - Roberts and Hedges' Clinical Procedures in Emergency Medicine.
PRP: Comparative studies show that although steroid gives faster relief, PRP provides greater and longer-lasting pain relief, with improvement persisting out to 2 years in some series - Campbell's Operative Orthopaedics, 15th Ed.
Multiple RCTs/meta-analyses (e.g., a 2020 systematic review of 653 patients) found PRP produced significantly lower pain scores than steroid at 6 months, 1 year, and 1.5 years follow-up, with better functional (foot/ankle) outcomes at mid-term.

4. Safety/risk profile

Steroid: Carries a real risk of plantar fascia rupture, along with fat pad atrophy and local tissue weakening, especially with repeated injections - Rheumatology, 2-Volume Set. This is the main reason many clinicians limit steroid injections to one, or avoid repeat dosing.
PRP: Being autologous, it avoids allergic/foreign-body reaction risk, and does not carry the fascia-rupture or fat-pad-atrophy risk associated with steroids. Downsides are cost, need for blood draw/processing, and less standardization of preparation protocols across studies.

5. Cost and practicality

Corticosteroid injection is cheaper, quicker to prepare, and technically simpler to perform - some reviews note there is no strong evidence that PRP (or botulinum toxin) outperforms corticosteroid injection enough to justify the added cost and complexity for every patient, though newer meta-analyses increasingly favor PRP for longer-term outcomes.

Bottom line

	Corticosteroid	PRP
Onset	Fast (days)	Slow (weeks)
Duration of benefit	Short (weeks to ~1 month)	Long (months to years)
Mechanism	Anti-inflammatory	Regenerative
Key risk	Fascia rupture, fat pad atrophy	Minimal (autologous), higher cost
Cost/convenience	Low cost, simple	Higher cost, more involved prep

In practice, many clinicians use steroid for a quick "rescue" of severe acute pain but favor PRP when the goal is longer-term resolution of chronic, recalcitrant plantar fasciitis, given emerging evidence of more durable improvement without the rupture risk.

Recent evidence check: A 2025 systematic review/meta-analysis (Zuo et al., PMID 39778212) and a 2023 meta-analysis on corticosteroid injections (Seth et al., PMID 36774828) both broadly support the pattern above - PRP shows superior mid- to long-term pain/function outcomes, while corticosteroid gives quicker but less durable relief. These don't contradict the textbook guidance, but confirm PRP's advantage is more consistently supported in recent literature than older textbooks suggested.BMP can refer to a couple of different things in medicine - let me confirm which one you mean.

Finding Sources

Reading File

Searching PubMed

"bone morphogenetic protein" AND spinal fusion

Searching the Web

bone morphogenetic protein clinical use orthopedics overview

Bone Morphogenetic Protein (BMP)

What it is BMPs are a family of growth factor proteins belonging to the transforming growth factor-beta (TGF-β) superfamily. They act as signaling molecules that regulate cell growth, differentiation, and tissue morphogenesis, with their best-known and most clinically exploited role being induction of bone and cartilage formation.

Mechanism BMPs bind to BMP receptors (BMPR) on mesenchymal stem cells and osteoprogenitor cells, activating intracellular Smad signaling pathways. This drives differentiation of these cells into osteoblasts and chondrocytes, stimulating new bone matrix deposition - essentially recapitulating the process of bone formation seen in embryonic skeletal development and fracture repair.

Clinical/orthopedic uses Recombinant human BMP (rhBMP, most commonly rhBMP-2) is used clinically to enhance bone healing in situations where the body's own repair capacity is insufficient:

Spinal fusion surgery (posterolateral and interbody lumbar fusion, where autograft is not feasible)
Acute open tibial shaft fractures
Nonunions and congenital pseudarthrosis of the tibia, typically as an adjunct alongside intramedullary fixation or other stabilization - Campbell's Operative Orthopaedics, 15th Ed.
Bone defect repair, often combined with carriers such as collagen sponges, hydroxyapatite, or bone substitutes, since rhBMP alone is less effective without a delivery scaffold

Other physiological roles Beyond bone, BMP signaling is also implicated in:

Vascular biology - mutations in the BMP receptor-II gene (BMPR2) cause familial pulmonary arterial hypertension, and drugs like sotatercept target this pathway - Goldman-Cecil Medicine
Iron metabolism - BMP signaling regulates hepcidin expression - Harper's Illustrated Biochemistry
Renal and rheumatologic disease processes, where BMP family members participate in tissue remodeling - Rheumatology, 2-Volume Set

Risks/controversies Use of rhBMP-2 in spinal fusion has raised concerns over complications such as ectopic bone formation, radiculitis, and postoperative swelling, and earlier reports raised a possible cancer signal - though a 2023 meta-analysis (PMID 37133762) found no clear correlation between rhBMP use and cancer incidence. A 2024 meta-analysis of nearly 5,900 patients (PMID 38701518) supports its efficacy in cervical arthrodesis with an acceptable complication profile when used appropriately.

Note: if you actually meant "BMP" as in Basic Metabolic Panel (the blood test measuring glucose, electrolytes, BUN, creatinine, etc.), let me know and I'll write that note instead - given our earlier discussion was orthopedic (PRP/plantar fasciitis), I assumed Bone Morphogenetic Protein was the intended meaning.

Write a short note on stem cell use in orthopedics

Finding Sources

Searching PubMed

"mesenchymal stem cell" AND orthopedic

Searching the Web

stem cell therapy orthopedics current clinical applications 2025

Stem Cell Use in Orthopedics

Stem cells, mainly mesenchymal stem cells (MSCs), are used in orthopedics to promote regeneration of bone, cartilage, tendon, and other musculoskeletal tissue rather than simply suppressing symptoms.

Sources of MSCs

Bone marrow-derived (BM-MSCs) - most studied, harvested from iliac crest
Adipose-derived (AD-MSCs) - obtained via liposuction, easier to harvest in larger quantities
Umbilical cord/Wharton's jelly and amniotic-derived - allogeneic sources used in some products

Mechanism MSCs have osteogenic, chondrogenic, and adipogenic differentiation potential, meaning they can become bone, cartilage, or fat-forming cells depending on the local environment. Beyond direct differentiation, a major part of their benefit comes from paracrine signaling - releasing growth factors and immunomodulatory cytokines that reduce local inflammation and recruit the body's own reparative cells, rather than the injected cells themselves fully repopulating the damaged tissue - Firestein & Kelley's Textbook of Rheumatology.

Clinical applications in orthopedics

Knee osteoarthritis: Intra-articular MSC injections are the most widely studied use. A 2025 systematic review/meta-analysis found MSC injections produced greater pain and functional improvement than hyaluronic acid injections at 12 months, with similar safety.
Cartilage repair/focal chondral defects: MSCs are used alone or combined with scaffolds to fill focal cartilage lesions, particularly in the knee and ankle.
Fracture nonunion and delayed union: MSCs (often combined with bone marrow aspirate concentrate) are injected or grafted at fracture sites to stimulate union, especially in recalcitrant nonunions - Rockwood and Green's Fractures in Adults, 10th Ed.
Tendon and ligament injuries: Applied in rotator cuff tears, tendinopathies, and partial ligament injuries to improve healing quality, though evidence here is less mature than for cartilage/bone.
Avascular necrosis of the femoral head: Core decompression combined with bone marrow-derived MSC injection is used in early-stage disease to try to preserve the femoral head and delay or avoid arthroplasty.
Spinal fusion/nonunion adjuncts: Occasionally combined with other biologics (e.g., BMP) in complex fusion or nonunion cases.

Evidence and limitations

Overall evidence quality is improving but still heterogeneous - trials vary widely in cell source, dose, preparation method, and concomitant treatments, making cross-study comparison difficult.
A 2025 systematic review (PMID 40898126) concluded MSC injections in trauma/orthopedics remain "a promising area with many uncertainties" rather than established standard practice - more standardized RCTs are needed before widespread adoption.
Regulatory status varies by country; in the US, most MSC orthopedic applications remain investigational or fall under specific FDA pathways (few products have full approval for orthopedic indications).
Cost, need for cell harvesting/processing, and lack of standardized dosing are practical barriers to routine use.

How it compares to other biologics MSCs sit alongside PRP and BMP as regenerative/biologic options in orthopedics - PRP concentrates the patient's own platelets and growth factors, BMP directly induces osteoblast differentiation for bone formation, while MSCs offer the broadest differentiation potential and immunomodulatory effect but come with more variable, less standardized clinical evidence to date.

Recent evidence flag: A 2025 meta-analysis (PMID 39154667, Jin et al., Arthroscopy) found MSC injections superior to hyaluronic acid for knee osteoarthritis, and a broader 2025 review (PMID 40898126) cautions that despite growing use, robust comparative RCT evidence in trauma/orthopedics is still lacking - worth keeping in mind before treating this as a fully established therapy.